by The behavioral rehabilitation market was estimated at US$ 150 billion last year and is projected to hit around US$ 208 billion by 2030, registering a CAGR of 3.7% between 2021 and 2030. The report contains 180+ pages with detailed analysis.
The global behavioral rehabilitation market is primarily driven by the rising prevalence of various mental health disorders such as anxiety, depression, substance abuse, and attention deficit disorders. The rising awareness regarding the availability of behavioral rehabilitation services, increasing awareness regarding mental health disorders, and increased expenditure on the health and wellness. The busy and hectic lifestyle of the consumers, sedentary lifestyle, rising unemployment, and rising attraction of youth towards illicit drugs are the major causes that may lead to various mental health disorders.
The government initiatives to spread awareness regarding the mental health and various treatments are major fueling the demand for the behavioral rehabilitation services across the globe. Moreover, the rising number of rehabilitation service providers across the global markets is boosting the growth and development of the behavioral rehabilitation market.
Moreover, the recent outbreak of the COVID-19 pandemic positively impacted the market growth. During the pandemic many people lost their jobs and stayed at their homes for prolonged time period. It resulted in depression, anxiety, and other mental disorders that spiked the demand for the rehabilitation services in 2020.
Download a Free Sample Pages (Including TOC, List of Tables & Figures, and Chart) @ https://www.precedenceresearch.com/sample/1377
Report Scope of the Behavioral Rehabilitation Market
| Report Highlights | Details |
| Market Size | USD 208 Billion by 2030 |
| Growth Rate | CAGR of 3.7% From 2021 to 2030 |
| Largest Market | North America |
| Fastest Growing Market | Asia Pacific |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Disorder Type, Application |
| Regional Scope |
|
North America dominated the global behavioral rehabilitation market in 2020, garnering a market share of over 40%. The rising prevalence of mental health disorders in the nation like US is the primary reason behind the dominance of this region. According to the US Department of Health and Human Services, around 20% of the children and adolescents suffered from mental disorders in their life at some point of time. Around 10% of people suffered from severe emotional disorders at some point in their life.
Moreover, the rising number of drug addicts has fueled the growth of the behavioral rehabilitation market. According to the United Nations Office on Drugs and Crime, in 2013, around 27 million people were suffering from drug use disorder. Around 24% to 36% of the heroin consuming population passes through correctional system annually in US. Furthermore, the rising government initiatives to promote mental wellness is fueling the demand or the rehabilitation services in the region.
Asia Pacific is estimated to be the most opportunistic market during the forecast period. Asia Pacific is expected to provide lucrative growth opportunities owing to the rising disposable income, presence of huge population of youth, rising consumer expenditure on health and wellness, growing number of rehabilitation service providers, and rising awareness regarding mental health disorders.
The rising awareness regarding the mental health disorders and awareness regarding the availability of behavioral rehabilitation services is fueling the demand for the rehabilitation services across the globe. Further, the increased efforts by the NGOs in spreading the awareness regarding the mental health are playing a positive role in the market growth.
The lack of awareness regarding the mental health disorders like anxiety, personality disorders, and depression in the underdeveloped economies is a major factor that may hinder the market growth. Further, the lack of proper healthcare infrastructure and lower penetration of behavioral rehabilitation services in the underdeveloped markets presents a major challenge for the market players.
The advancements in the field of various therapies like cognitive behavioral therapy and the various developmental strategies adopted by the top market players are expected to offers growth opportunities in the upcoming future.
Based on the disorder type, the anxiety segment dominated the market in 2020. This is attributed to the increased cases of anxiety across the globe.According to a study, in 2017, around 284 million people were estimated to be suffering from anxiety disorder, globally. According to the Anxiety and Depression Association of America, around 18.1% of the US population aged 18 years or above suffers from anxiety each year. But only around 37% of the patients gets treatment. Anxiety is the most common mental disorder and hence is expected to sustain its dominance during the forecast period.
Read Also: Over the Counter Drugs Market Expected to Reach US$294.18 Billion by 2030
Based on the application, the outpatient was the dominant and is expected to be the most opportunistic market during the forecast period. This is attributed to the freedom and convenience offered by the outpatient care. In outpatient care, the patient receives the treatment in the rehabilitation center during day time and then the patient is allowed to go back to their home and families. This offers convenience to the patient and his family and hence it is gaining rapids traction in the market.
In May 2020, Limbix received around US$ 9 million in series A funding, which will be utilized to develop digital therapeutics for the teens who are suffering from depression. The various developmental strategies like acquisition, partnerships, mergers, and government policies fosters market growth and offers lucrative growth opportunities to the market players.
The key players profiled in the global behavioral rehabilitation market are
- Allergan, Inc.
- Novartis AG
- Taro Pharmaceutical Industries
- Perrigo Company plc
- Zynerba Pharmaceuticals
- Apotex Inc.
- Sandoz AG
- Strides Arcolab Ltd.
- TOLMAR Pharmaceuticals, Inc.
- Limbix
Market Segmentation
By Disorder Type
- Mood Disorders
- Anxiety Disorders
- Personality Disorders
- Substance Abuse Disorders
- Attention Deficit Disorders
By Application
- Outpatient
- Inpatient
- Residential
Regional Segmentation
- North America (U.S. and Canada)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Behavioral Rehabilitation Market
5.1. COVID-19 Landscape: Behavioral Rehabilitation Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Behavioral Rehabilitation Market, By Disorder
8.1. Behavioral Rehabilitation Market, by Disorder Type, 2021-2030
8.1.1. Mood Disorders
8.1.1.1. Market Revenue and Forecast (2019-2030)
8.1.2. Anxiety Disorders
8.1.2.1. Market Revenue and Forecast (2019-2030)
8.1.3. Personality Disorders
8.1.3.1. Market Revenue and Forecast (2019-2030)
8.1.4. Substance Abuse Disorders
8.1.4.1. Market Revenue and Forecast (2019-2030)
8.1.5. Attention Deficit Disorders
8.1.5.1. Market Revenue and Forecast (2019-2030)
Chapter 9. Global Behavioral Rehabilitation Market, By Application
9.1. Behavioral Rehabilitation Market, by Application, 2021-2030
9.1.1. Outpatient
9.1.1.1. Market Revenue and Forecast (2019-2030)
9.1.2. Inpatient
9.1.2.1. Market Revenue and Forecast (2019-2030)
9.1.3. Residential
9.1.3.1. Market Revenue and Forecast (2019-2030)
Chapter 10. Global Behavioral Rehabilitation Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.1.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.1.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.1.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.2.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.2.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.2.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.2.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.2.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.3.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.3.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.3.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.3.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.4.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.4.4.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.4.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.4.6.2. Market Revenue and Forecast, by Application (2019-2030)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.5.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.5.3.2. Market Revenue and Forecast, by Application (2019-2030)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Disorder (2019-2030)
10.5.4.2. Market Revenue and Forecast, by Application (2019-2030)
Chapter 11. Company Profiles
11.1. Allergan, Inc.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Novartis AG
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Taro Pharmaceutical Industries
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Perrigo Company plc
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Zynerba Pharmaceuticals
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Apotex Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Sandoz AG
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Strides Arcolab Ltd.
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. TOLMAR Pharmaceuticals, Inc.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Limbix
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Buy this Premium Research Report@https://www.precedenceresearch.com/checkout/1377
